Two Biotechs Just Rang the IPO Bell on the Same Day

The company's secret sauce is its Glyph platform, which works a bit like rerouting a package through a different shipping lane. Most oral drugs get broken down in the liver before they can do much good (that's called first-pass metabolism). Glyph sends drugs through the lymphatic system instead, like dietary fats do, boosting how much active drug actually reaches the brain while cutting side effects.

Seaport's lead candidate, GlyphAllo, is in Phase 2b testing for major depressive disorder. The depression market is enormous and crowded, with up to 50% of patients getting inadequate relief from standard antidepressants. Novel mechanisms are in high demand: NMDA antagonists as a class already hold over 40% of treatment-resistant depression revenue, and psychedelic-based therapies are advancing through Phase 3 trials. Seaport is betting that neurosteroids delivered through its Glyph platform can carve out meaningful share in a market projected to exceed $2 billion.

Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are running the books. The proposed ticker? SPTX.

Hemab: Fixing Platelets That Don't Work

Hemab Therapeutics is solving a very different problem, but with equally sharp focus. The company develops antibody-based therapies for rare inherited bleeding disorders, the kind of conditions where patients can bleed severely from a minor bump because their blood simply can't clot properly.

Their lead drug, sutacimig, targets Glanzmann thrombasthenia, a rare condition caused by faulty platelet receptors. Imagine your blood cells are trying to form a clot, but the velcro that's supposed to hold them together is missing. That's Glanzmann. Sutacimig is designed to restore that sticking ability, and it's already completed Phase 2 with positive results. The IPO proceeds will fund a Phase 3 registration study, which is the final step before seeking approval.

Hemab also has a second program, HMB-002, in Phase 1/2 for Von Willebrand disease, another bleeding disorder with limited treatment options.

The company isn't exactly strapped for cash. Hemab has raised funding across seed, Series A, Series B, and a $157 million Series C in October 2025. Backers include Novo Holdings (which helped create the company in 2020), Sofinnova Partners, RA Capital, and a sovereign wealth fund. Goldman Sachs, Jefferies, Evercore ISI, and Wedbush PacGrow are managing the offering under the ticker COAG (as in coagulation; someone on the naming committee deserves a raise).

Two Very Different Bets, One Shared Thesis

On paper, these companies couldn't be more different. Seaport is chasing a massive, competitive market in depression with a platform play. Hemab is pursuing ultra-rare diseases where the patient populations are small but the unmet need is enormous and competition is thin.

But they share a profile that Wall Street has been rewarding: clinical-stage programs with real human data, experienced leadership, strong venture syndicates, and clear paths to pivotal trials. That's the formula that's been working in 2026's selective IPO market.

The bigger picture matters too. Q1's $1.7 billion haul was impressive, but performance has been mixed once companies start trading. Platform-oriented biotechs that priced lucrative IPOs have, in some cases, slipped below their offering price. Product-focused companies with single validated programs have fared better. Hemab, with its rare disease focus and Phase 3-ready asset, fits the latter mold. Seaport, with its platform technology and broader pipeline ambitions, is testing whether the market will pay for bigger visions.

What to Watch

Neither company has set a price range or share count yet. Both filings note that completion depends on market conditions, which is standard legal language but also genuinely true in a market rattled by geopolitical concerns and FDA leadership turnover.

For Seaport, the key catalyst is the Phase 2b readout for GlyphAllo. Positive results would validate the entire Glyph platform and potentially unlock the value of their anxiety and CNS pipeline behind it. For Hemab, the Phase 3 trial for sutacimig in Glanzmann thrombasthenia is the main event, with registration data that could put them on a path to approval in a space with very few competitors.

Two companies, two diseases, one shared bet: that public investors are ready to fund the next generation of biotech innovation. The IPO window is open. The question is how long it stays that way.